Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial

Autor: Heller, S. R., Bergenstal, R. M., White, W. B., Kupfer, S., Bakris, G. L., Cushman, W. C., Mehta, C. R., Nissen, S. E., Wilson, C. A., Zannad, F., Liu, Y., Gourlie, N. M., Cannon, C. P., EXAMINE Investigators, E. I.

AIMS: To investigate relationships between glycated haemoglobin (HbA1c) and reported hypoglycaemia and risk of major adverse cardiovascular events (MACE). METHODS: The EXAMINE trial randomized 5380 patients with type 2 diabetes (T2DM) and a recent ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::75ba76cfc0aaae64134871f3ad2f6f72
https://eprints.whiterose.ac.uk/110784/7/Heller_et_al-2017-Diabetes,_Obesity_and_Metabolism.pdf

LEADER 2:baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

Autor: Moses, A. C., Derving Karsbøl, J., Mann, J. F. E., Bergenstal, R. M., Nauck, M. A., Marso, S. P., Hegedüs, L., Tuttle, R. M., Zinman, B., Daniels, G. H., Buse, J. B.

Publikováno v: Daniels, G H, Hegedüs, L, Marso, S P, Nauck, M A, Zinman, B, Bergenstal, R M, Mann, J F E, Derving Karsbøl, J, Moses, A C, Buse, J B, Tuttle, R M & LEADER trial investigators 2015, ' LEADER 2 : baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations ', Diabetes, Obesity and Metabolism, vol. 17, no. 5, pp. 477-486 . https://doi.org/10.1111/dom.12444

AIMS: To report preliminary data on baseline serum calcitonin concentrations and associated clinical characteristics in a global population with type 2 diabetes before liraglutide or placebo randomization.METHODS: The ongoing LEADER trial has enrolle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::255a03fa30e6f8f87fb0efe9fa772be8
https://portal.findresearcher.sdu.dk/da/publications/6b126135-3229-45a0-91de-3007d2a84f89

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Autor: Sherman, S. I., Drucker, D. J., Gorelick, F. S., Buse, J. B., Bergenstal, R. M., Sherwin, R. S.

Limited evidence suggests that GLP-I may also preserve ventricular function and improve outcomes in human subjects with heart failure or myocardial infarction (11,12). [...] both exenatide and liraglutide reduce blood pressure, body weight, and plasm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f495f2f34a32a34ee69a8bc32caa34a

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.